Posts Tagged ‘EMPHASIS-HF’

August 30th, 2011

New Results from EMPHASIS-HF Show Big Benefits For High-Risk Subgroups Taking Eplerenone

Last November the main results of the EMPHASIS-HF trial demonstrated that eplerenone was significantly better than placebo in reducing the risk for death and hospitalization in patients with systolic heart failure and mild symptoms. Now a new analysis of the trial, presented by Bertram Pitt at the European Society of Cardiology meeting in Paris, reinforces the earlier findings […]

May 23rd, 2011

Eplerenone Found to Also Reduce AF in Heart Failure Patients

Results from EMPHASIS-HF (Eplerenone and Atrial Fibrillation in Patients with Systolic Heart Failure and Mild Symptoms) previously showed that adding the aldosterone antagonist eplerenone to standard therapy in patients with NYHA class II heart failure resulted in the reduction of the composite endpoint of death from cardiovascular causes or hospitalization for heart failure. Now, a […]